Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

NCRI 2010 /
Chemoradiotherapy for bladder cancer

7th - 10th Nov 2010

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.01.11
Views: 6070
Rating:

Prof Nick James - Queen Elizabeth Hospital and University of Birmingham, UK

Prof Nick James explains the results of his study into chemoradiotherapy for patients with bladder cancer. Radiotherapy alone is associated with a high recurrence rate, but when successful it is superior to surgery. This study demonstrated that combining fluorouracil and mitomycin C as radiosensitisers reduces locoregional recurrence by 33%. The reduction in recurrence rate was primarily in invasive recurrences rather than less serious superficial recurrences and the addition of the radiosensitisers only produced a minimal increase in side effects. Prof James speaks about the background to this study, discusses how the fluorouracil mitomycin C radiosensitiser combination was chosen and briefly outlines the second part of the trial which examined how a reduction in radiotherapy dose affected toxicity.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation